Browsing by Author "Saini, Sarbjit S."

Sort by: Order: Results:

  • Maurer, Marcus; Metz, Martin; Bindslev Jensen, Carsten; Bousquet, Jean; Canonica, G. Walter; Church, Martin K.; Godse, Kiran V.; Grattan, Clive; Hide, Michihiro; Kocatürk, Emek; Magerl, M.; Makris, Michael; Meshkova, R. Y.; Saini, Sarbjit S.; Sussman, Gordon; Toubi, Elias; Zhao, Zuotao; Zuberbier, Torsten; Giménez Arnau, Anna Maria (Wiley, 2016)
    BACKGROUND: GA²LEN, the Global Allergy and Asthma European Network, has recently launched a program for the development, interaction, and accreditation of centers of reference and excellence in special areas of allergy ...
  • Kaplan, Allen P.; Giménez Arnau, Anna Maria; Saini, Sarbjit S. (Wiley, 2017)
    The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 -antihistamine ...
  • Casale, Thomas B.; Bernstein, Jonathan A.; Maurer, Marcus; Saini, Sarbjit S.; Trzaskoma, Benjamin; Chen, Hubert; Clive, Grattan; Giménez Arnau, Anna Maria; Kaplan, Allen P.; Rosén, Karin (Elsevier, 2015)
    BACKGROUND: Data from the 3 omalizumab pivotal trials in patients with chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) represent the largest database of patients reported to date with refractory disease ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking